|
|
|
|
|
|
|
|
|
|
|
|
|
10.09.26 - 12:12
|
Hong Kong watchdog investigates Cloudbreak Pharma for ′rigged′ IPO, suspends its shares (SCMP)
|
|
|
Hong Kong's Securities and Futures Commission (SFC) has directed the stock exchange to suspend trading of US-based biotech firm Cloudbreak Pharma pending an investigation into its US$78 million initial public offering (IPO) last year.
“The SFC has serious concerns that Cloudbreak's initial public offering may have been rigged to create an artificial impression of demand for Cloudbreak's shares,” the SFC said in a statement on Thursday.
The regulator considered the suspension “necessary or......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
09.09.26 - 08:06
|
As China embraces AI, only 24% of US pharma execs bet on it for drug-making (SCMP)
|
|
|
Pharmaceutical companies have embraced artificial intelligence in drug research almost universally, yet few company executives expect AI to actually make drugs succeed, according to a Citi survey released on Tuesday.
“The biggest risk to the AI-powered drug discovery thesis is not that AI fails to accelerate discovery,” said John Yung, head of Asia healthcare research at the US investment bank. “The stronger risk is that acceleration does not translate into better drugs or higher probability of......
|
|
|
09.09.26 - 07:06
|
China needs monkeys: lab animal shortage could hinder biotech growth (SCMP)
|
|
|
China's biotechnology market has “significantly” driven up the demand for primate experimental models as the market recovers, tightening the supply of laboratory monkeys, according to a leading biotech firm.
The continued recovery of fundraising and out-licensing deals in innovative drugs in China this year has led to significant growth in the demand for primate experimental models, research firm Joinn Laboratories (China) said on Tuesday.
Primate experiments typically use monkeys and other......
|
|
|
|
|
08.09.26 - 20:06
|
AI Healthcare Startup Forus Hits $3 Billion Valuation (Bloomberg)
|
|
|
Healthcare automation startup Forus has raised $150 million at a $3 billion valuation, tripling its value just months after its previous funding round. CEO Sahir Jaggi explains how the company uses AI agents to help patients and doctors navigate insurance coverage, affordability, and drug fulfillment. He also explains how the new capital will help Forus expand beyond autoimmune diseases into areas including oncology and neurology. He joins Bloomberg's Riley Griffin on "Bloomberg Tech." (Source: Bloomberg)...
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
